What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
Krensavage Asset Management, according to an SEC filing dated May 14, 2026, bought 241,245 shares of Ultragenyx Pharmaceutical (RARE), an estimated $5.43 million based on quarterly average pricing. The fund ended the quarter with 390,879 shares valued at $8.19 million. RARE shares were about $23.94, down roughly 32% over the past year.
How this was made
The 30-second read
Why it matters
The purchase is framed as a long-term bet on an inflection narrative: 2026 turning-point catalysts (potential approvals and a Phase 3 GTX-102 readout), plus restructuring to improve the financial profile and a 2026 product-revenue outlook.
Market read
For traders, the actionable signal is sentiment/positioning rather than a new fundamental print; it may modestly support downside stabilization if catalysts are credible.
What to watch
The article doesn’t provide trade timing (only quarterly/filing-based averages), and RARE’s large net loss and restructuring could still pressure valuation regardless of the buy.
Background
Krensavage Asset Management reported a first-quarter increase in its Ultragenyx stake via SEC 13F disclosure dated May 14, 2026.
Ticker impact
Krensavage disclosed a 241,245-share increase in Ultragenyx (RARE), valued at about $5.43M, while RARE shares are down ~32% YoY.
Near-term impact likely limited, but could support dip-buying flows if the market is already positioned for upcoming approvals/readouts.
The article is an ownership/positioning update (13F) rather than a fundamental catalyst; it can influence sentiment but is not a new clinical or financial datapoint.
Market effects
Reinforces that rare-disease biotech investors may be selectively accumulating names with near-term approval/readout windows.
Primarily US biotech sentiment; no explicit cross-region catalyst described.
Limited—story is US-listed ownership disclosure tied to RARE’s 2026 pipeline and commercialization.
Counterpoint
13F changes can lag true conviction and may reflect portfolio rebalancing rather than a specific view on imminent trial/approval outcomes.
Key entities
- companyUltragenyx Pharmaceutical
RARE, rare-disease biotech; shares down ~32% YoY; 13F buying highlighted alongside 2026 catalysts and restructuring plan.
- institutionKrensavage Asset Management
Reported increased ownership in RARE (241,245 shares; ~$5.43M estimated) in its SEC 13F disclosure.
- personEmil Kakkis
CEO cited describing 2026 as an important turning point for approvals and Phase 3 GTX-102 data.
